• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia.谨防一概而论：头孢他啶-阿维巴坦与美罗培南治疗革兰阴性菌肺炎的比较
J Emerg Crit Care Med. 2018 May;2. doi: 10.21037/jeccm.2018.05.02. Epub 2018 May 15.
2
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.头孢他啶-阿维巴坦与美罗培南治疗医院获得性肺炎，包括呼吸机相关性肺炎（REPROVE）：一项随机、双盲、III 期非劣效性试验。
Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16.
3
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
4
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.头孢他啶-阿维巴坦：一种用于治疗耐药革兰氏阴性菌的新型头孢菌素/β-内酰胺酶抑制剂组合
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
5
Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.2011年至2015年在美国医疗中心住院治疗肺炎的患者中分离出的革兰氏阴性菌对头孢他啶-阿维巴坦的抗菌活性
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02083-16. Print 2017 Apr.
6
The β-Lactams Strike Back: Ceftazidime-Avibactam.β-内酰胺类药物卷土重来：头孢他啶-阿维巴坦
Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622.
7
Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012).头孢他啶/阿维巴坦对美国医疗中心血源、肺炎、腹腔内和尿路感染分离的革兰氏阴性菌的活性检测（2012 年）。
J Antimicrob Chemother. 2014 Jun;69(6):1589-98. doi: 10.1093/jac/dku025. Epub 2014 Feb 20.
8
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.头孢他啶/阿维巴坦对重症监护病房（ICU）和非 ICU 患者的革兰氏阴性菌进行了测试，包括呼吸机相关性肺炎患者。
Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.
9
In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.头孢他啶/阿维巴坦对住院肺炎患者（包括呼吸机治疗患者）分离的革兰氏阴性病原体的体外活性。
Int J Antimicrob Agents. 2016 Mar;47(3):235-42. doi: 10.1016/j.ijantimicag.2016.01.004. Epub 2016 Feb 3.
10
Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012-2014.2012 - 2014年美国医院腹腔内感染分离出的需氧革兰阴性菌对头孢他啶 - 阿维巴坦的敏感性
Surg Infect (Larchmt). 2016 Aug;17(4):473-8. doi: 10.1089/sur.2016.036. Epub 2016 Apr 22.

引用本文的文献

1
New cephalosporins for the treatment of pneumonia in internal medicine wards.用于内科病房治疗肺炎的新型头孢菌素
J Thorac Dis. 2020 Jul;12(7):3747-3763. doi: 10.21037/jtd-20-417.

本文引用的文献

1
In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.产 KPC 肺炎克雷伯菌在头孢他啶/阿维巴坦治疗期间耐药亚群的体内进化。
J Antimicrob Chemother. 2018 Jun 1;73(6):1525-1529. doi: 10.1093/jac/dky082.
2
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.肺炎和肾脏替代治疗是耐碳青霉烯类肠杆菌科感染患者使用头孢他啶-阿维巴坦治疗失败和耐药的危险因素。
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.02497-17. Print 2018 May.
3
Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia.阿维巴坦+头孢他啶治疗医院获得性肺炎的药代动力学药物评价
Expert Opin Drug Metab Toxicol. 2018 Mar;14(3):331-340. doi: 10.1080/17425255.2018.1434142. Epub 2018 Jan 31.
4
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
5
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.头孢他啶-阿维巴坦与美罗培南治疗医院获得性肺炎，包括呼吸机相关性肺炎（REPROVE）：一项随机、双盲、III 期非劣效性试验。
Lancet Infect Dis. 2018 Mar;18(3):285-295. doi: 10.1016/S1473-3099(17)30747-8. Epub 2017 Dec 16.
6
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.多黏菌素与头孢他啶-阿维巴坦治疗碳青霉烯类耐药肠杆菌科细菌感染。
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
7
Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.对头孢他啶-阿维巴坦的耐药性是由于产孔蛋白缺陷的肺炎克雷伯菌中 KPC 的转位和增加的外排活性。
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00989-17. Print 2017 Oct.
8
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.头孢他啶-阿维巴坦在治疗耐碳青霉烯类肺炎克雷伯菌血症方面优于其他治疗方案。
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
9
Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.多粘菌素：抗菌活性、药敏试验以及由质粒或染色体编码的耐药机制
Clin Microbiol Rev. 2017 Apr;30(2):557-596. doi: 10.1128/CMR.00064-16.
10
Population Structure of Klebsiella pneumoniae Causing Bloodstream Infections at a New York City Tertiary Care Hospital: Diversification of Multidrug-Resistant Isolates.纽约市一家三级护理医院中引起血流感染的肺炎克雷伯菌的种群结构：多重耐药菌株的多样化
J Clin Microbiol. 2015 Jul;53(7):2060-7. doi: 10.1128/JCM.03455-14. Epub 2015 Apr 15.

Beware of broad-spectrum generalizations: ceftazidime-avibactam compared to meropenem for the treatment of gram-negative pneumonia.

作者信息

Mehta Monica, Uhlemann Anne-Catrin

机构信息

NewYork-Presbyterian Hospital, New York, NY, USA.

Department of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, NY, USA.

出版信息

J Emerg Crit Care Med. 2018 May;2. doi: 10.21037/jeccm.2018.05.02. Epub 2018 May 15.

DOI:10.21037/jeccm.2018.05.02
PMID:30123873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6097712/
Abstract
摘要